Skip to main content
SpringerLink
Log in

PVC13 cost effective in at-risk elderly in Belgium

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 euros

Reference

  • Marbaix S, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLOS One : 6 Jul 2018. Available from: URL: https://doi.org/10.1371/journal.pone.0199427

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PVC13 cost effective in at-risk elderly in Belgium. PharmacoEcon Outcomes News 808, 25 (2018). https://doi.org/10.1007/s40274-018-5140-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5140-7

Search

Navigation